title: β-blockers: a new role in cancer chemotherapy?
abstract: β-blockers are a class of drugs that are widely used in treating cardiac, respiratory and other ailments. They act by blocking β-adrenergic receptor-mediated signaling. Studies in various cancers have shown that patients taking a β-blocker have higher survival and lower recurrence and metastasis rates. This is supported by several preclinical and in vitro studies showing that adrenergic activation modulates apoptosis, promotes angiogenesis and other cancer hallmarks, and these effects can be abrogated by β-blockers. These studies provide a rationale for the use of β-blockers as adjuvants with cancer chemotherapy. However, all published studies so far are retrospective and most do not take into account the specific β-blocker used or address which is most likely to benefit cancer patients. The published epidemiological studies are correlative and have not examined the adrenergic receptor status of the tumors. Knowledge of the β-adrenergic receptor status of tumor cells is essential in choosing the best β-blocker for adjuvant therapy. A comprehensive, prospective study is necessary to definitively prove the utility of using β-blockers with chemotherapy and to identify the specific β-blocker most likely to benefit patients with cancer.
authors.affiliation: The University of Texas MD Anderson Cancer Center, Department of Gynecologic Oncology and Reproductive Medicine , Houston, TX 77030 , USA.
authors.forename: Archana S
authors.initials: AS
authors.lastname: Nagaraja
authors.forename: Nouara C
authors.initials: NC
authors.lastname: Sadaoui
authors.forename: Susan K
authors.initials: SK
authors.lastname: Lutgendorf
authors.forename: Lois M
authors.initials: LM
authors.lastname: Ramondetta
authors.forename: Anil K
authors.initials: AK
authors.lastname: Sood
mesh_terms: D000277:Adjuvants, Pharmaceutic / Q000008:administration & dosage; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D000277:Adjuvants, Pharmaceutic; D000319:Adrenergic beta-Antagonists; D000970:Antineoplastic Agents
references.citation: J Natl Cancer Inst Monogr. 2004;(32):57-71
references.pmid: 15263042
references.citation: N Engl J Med. 2008 Jun 12;358(24):2649-51
references.pmid: 18550886
references.citation: Eur Urol. 2014 Mar;65(3):635-41
references.pmid: 23351721
references.citation: Oncotarget. 2010 Nov;1(7):628-38
references.pmid: 21317458
references.citation: Ann Oncol. 2013 May;24(5):1312-9
references.pmid: 23300016
references.citation: Gynecol Oncol. 2012 Nov;127(2):375-8
references.pmid: 22819786
references.citation: J Oral Pathol Med. 2009 Apr;38(4):371-6
references.pmid: 19141064
references.citation: J Clin Oncol. 2011 Jul 1;29(19):2645-52
references.pmid: 21632501
references.citation: J Clin Oncol. 2011 Jul 1;29(19):2635-44
references.pmid: 21632503
references.citation: Gynecol Oncol. 2013 Jun;129(3):463-6
references.pmid: 23500609
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2007 Aug 15;31(6):1242-7
references.pmid: 17587477
references.citation: Nat Commun. 2013;4:1403
references.pmid: 23360994
references.citation: Brain Behav Immun. 2011 Feb;25(2):250-5
references.pmid: 20955777
references.citation: Cancer. 2005 Jul 15;104(2):305-13
references.pmid: 15954082
references.citation: Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2273-9
references.pmid: 21933972